Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 21, 2022

Primary Completion Date

October 8, 2024

Study Completion Date

December 12, 2024

Conditions
Iron Deficiency, Anaemia
Interventions
DRUG

Ferric carboxymaltose

Intravenous

Trial Locations (4)

11040

Cohen Children's Medical Center, New Hyde Park

19134

St. Christopher's Hospital for Children, Philadelphia

43205

Nationwide Children's Hospital, Columbus

52242

University of Iowa, Iowa City

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY

NCT04968379 - Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia | Biotech Hunter | Biotech Hunter